RenovoRx, Inc. financial data

Symbol
RNXT on Nasdaq
Industry
Pharmaceutical Preparations
Location
333 W. Santa Clara Street, Suite 900, San Jose, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 171 % +271%
Return On Equity -403 % -91.5%
Return On Assets -149 % -3.32%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24M shares +124%
Common Stock, Shares, Outstanding 24M shares +124%
Entity Public Float 15.5M USD 0%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 24M shares +126%
Weighted Average Number of Shares Outstanding, Diluted 24M shares +126%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.2M USD +6.51%
General and Administrative Expense 5.07M USD -16.7%
Operating Income (Loss) -10.3M USD +6.36%
Nonoperating Income (Expense) 2.16M USD +97.7%
Net Income (Loss) Attributable to Parent -8.11M USD +17.9%
Earnings Per Share, Basic -0.58 USD/shares +44.8%
Earnings Per Share, Diluted -0.58 USD/shares +54.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.7M USD +97.2%
Marketable Securities, Current 2.05M USD
Cash, Cash Equivalents, and Short-term Investments 6.4M USD
Assets, Current 7.27M USD -55.4%
Assets 12M USD +90.1%
Accounts Payable, Current 438K USD -49.8%
Accrued Liabilities, Current 873K USD +5.56%
Liabilities, Current 1.31M USD -22.8%
Liabilities 2.73M USD -46.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 17K USD
Retained Earnings (Accumulated Deficit) -44.9M USD -22.1%
Stockholders' Equity Attributable to Parent 9.27M USD +680%
Liabilities and Equity 12M USD +90.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.2M USD +18.6%
Net Cash Provided by (Used in) Financing Activities 5.42M USD +90233%
Net Cash Provided by (Used in) Investing Activities 2.03M USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 24M shares +124%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.22M USD
Deferred Tax Assets, Valuation Allowance 12.7M USD +43.5%
Deferred Tax Assets, Gross 12.7M USD +43.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.39M USD -2.66%
Deferred Tax Assets, Operating Loss Carryforwards 8.87M USD +36.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares
Unrecognized Tax Benefits 646K USD +43.9%
Additional Paid in Capital 54.1M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 18K USD
Share-based Payment Arrangement, Expense 239K USD +67.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares